Ehsan Razeghian
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
-
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 5
- CAR-T cell therapy research 3
- Pancreatic and Hepatic Oncology Research 1
-
- CRISPR and Genetic Engineering 3
- Viral Infectious Diseases and Gene Expression in Insects 1
- Co-authors
- Wanich Suksatan (2 shared papers)Lakshmi Thangavelu (2 shared papers)Rebar N. Mohammed (1 shared paper)Ali Noroozi‐Aghideh (1 shared paper)Mohammed Nader Shalaby (1 shared paper)Navid Shomali (1 shared paper)Adel Naimi (1 shared paper)Ali Adili (1 shared paper)
In The Last Decade
Ehsan Razeghian
10 papers receiving 500 citations
Ehsan Razeghian's Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 269
- Immunology 159
- Cancer Research 42
- Business and International Management 5
- Molecular Biology 162
Countries citing papers authored by Ehsan Razeghian
This map shows the geographic impact of Ehsan Razeghian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ehsan Razeghian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ehsan Razeghian more than expected).
Fields of papers citing papers by Ehsan Razeghian
This network shows the impact of papers produced by Ehsan Razeghian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ehsan Razeghian. The network helps show where Ehsan Razeghian may publish in the future.
Co-authors
The 25 scholars most cited alongside Ehsan Razeghian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons Hit paper breakdown → | 2022 | 339 |
| 2 | 2021 | 94 | |
| 3 | 2021 | 27 | |
| 4 | 2023 | 15 | |
| 5 | 2022 | 15 | |
| 6 | 2021 | 6 | |
| 7 | 2021 | 4 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 1 | |
| 10 | 2020 | 1 |
About Ehsan Razeghian
Ehsan Razeghian is a scholar working on Oncology, Molecular Biology, Genetics, Rheumatology and Public Health, Environmental and Occupational Health, having authored 10 papers that have together received 503 indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (3 papers), CAR-T cell therapy research (3 papers), Mesenchymal stem cell research (2 papers), Acute Myeloid Leukemia Research (1 paper), Viral Infectious Diseases and Gene Expression in Insects (1 paper), Pancreatic and Hepatic Oncology Research (1 paper), Osteoarthritis Treatment and Mechanisms (1 paper) and Nanowire Synthesis and Applications (1 paper). The work is most often cited by research in Oncology (269 citations), Immunology (159 citations), Cancer Research (42 citations), Business and International Management (5 citations) and Molecular Biology (162 citations). Ehsan Razeghian has collaborated with scholars based in Iran, Iraq and India. Frequent co-authors include Wanich Suksatan, Lakshmi Thangavelu, Rebar N. Mohammed, Ali Noroozi‐Aghideh, Mohammed Nader Shalaby, Navid Shomali, Adel Naimi, Ali Adili, Alexei Valerievich Yumashev and Ahmed Raji. Their work appears in journals such as Molecular Biology Reports, International Immunopharmacology, Cell Biology International, Stem Cell Research & Therapy and Sexual Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.